Marzia A. Locatelli

Bergamo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?

Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 20, 2026

"Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?"

"Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?"

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 15, 2026

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 17, 2025

Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities.

Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities.

Journal: Current oncology (Toronto, Ont.)

Published: August 17, 2025

Lung Carcinoids in Adolescents and Young Adults (AYAs): A Still Overlooked Clinical Entity.

Lung Carcinoids in Adolescents and Young Adults (AYAs): A Still Overlooked Clinical Entity.

Journal: Current oncology (Toronto, Ont.)

Published: June 26, 2025

Heterogeneity of progression-free survival surrogacy by sex in randomized trials testing immunotherapy in non-small cell lung cancer.

Heterogeneity of progression-free survival surrogacy by sex in randomized trials testing immunotherapy in non-small cell lung cancer.

Journal: JNCI cancer spectrum

Published: March 24, 2025

Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates.

Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates.

Journal: Journal of the National Cancer Institute

Published: September 13, 2024

Sex hormones, the anticancer immune response, and therapeutic opportunities.

Sex hormones, the anticancer immune response, and therapeutic opportunities.

Journal: Cancer cell

Published: July 08, 2024

Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials.

Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 03, 2024

The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility.

The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility.

Journal: Critical reviews in oncology/hematology

Published: July 31, 2023

Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.

Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.

Journal: The oncologist

Published: March 05, 2023

Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.

Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.

Journal: The oncologist

Published: December 19, 2022

Showing 1-12 of 38

Last Updated: 09/26/2026